An Epithelial-to-Mesenchymal transcriptional switch triggers evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and identifies dasatinib as new therapeutic option.

Conclusions: Our data provide new insights into PSC evolution and provide the rationale for further clinical studies with dasatinib.
PMID: 30587547 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 26, 2018 Category: Cancer & Oncology Authors: Manzotti G, Torricelli F, Donati B, Lococo F, Sancisi V, Rossi G, Piana S, Ciarrocchi A Tags: Clin Cancer Res Source Type: research